RT Journal Article
SR Electronic
T1 Oncogenic Fusions in Gliomas: An Institutional Experience
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1933
OP 1939
DO 10.21873/anticanres.15671
VO 42
IS 4
A1 JIRI POLIVKA
A1 MARIAN SVAJDLER
A1 VLADIMIR PRIBAN
A1 JAN MRACEK
A1 PETR KASIK
A1 PETR MARTINEK
A1 NIKOLA PTAKOVA
A1 MAHYAR SHARIF BAGHERI
A1 DATTATRYA SHETTI
A1 MARTIN PESTA
A1 PAVEL POTUZNIK
A1 ONDREJ TOPOLCAN
YR 2022
UL http://ar.iiarjournals.org/content/42/4/1933.abstract
AB Background/Aim: Gliomas are primary malignancies of the central nervous system (CNS). High-grade gliomas are associated with poor prognosis and modest survival rates despite intensive multimodal treatment strategies. Targeting gene fusions is an emerging therapeutic approach for gliomas that allows application of personalized medicine principles. The aim of this study was to identify detectable fusion oncogenes that could serve as predictors of currently available or newly developed targeted therapeutics in cross-sectional samples from glioma patients using next-generation sequencing (NGS). Patients and Methods: A total of 637 patients with glial and glioneuronal tumours of the CNS who underwent tumour resection between 2017 and 2020 were enrolled. Detection of fusion transcripts in FFPE tumour tissue was performed by a TruSight Tumour 170 assay and two FusionPlex kits, Solid Tumour and Comprehensive Thyroid and Lung. Results: Oncogene fusions were identified in 33 patients. The most common fusion was the KIAA1549-BRAF fusion, detected in 13 patients, followed by FGFR fusions (FGFR1-TACC1, FGFR2-CTNNA3, FGFR3-TACC3, FGFR3-CKAP5, FGFR3-AMBRA1), identified in 10 patients. Other oncogene fusions were also infrequently diagnosed, including MET fusions (SRPK2-MET and PTPRZ1-MET) in 2 patients, C11orf95-RELA fusions in 2 patients, EGFR-SEPT14 fusion in 2 patients, and individual cases of SRGAP3-BRAF, RAF1-TRIM2, EWSR1-PALGL1 and TERT-ALK fusions. Conclusion: The introduction of NGS techniques provides additional information about tumour molecular alterations that can aid the multimodal management of glioma patients. Patients with gliomas positive for particular targetable gene fusions may benefit from experimental therapeutics, enhancing their quality of life and prolonging survival rates.